Department of Endocrinology and Metabolism and the Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, China Medical University, Shenyang, China.
Front Immunol. 2022 Aug 11;13:953465. doi: 10.3389/fimmu.2022.953465. eCollection 2022.
BACKGROUND: Autoimmune thyroiditis (AIT) is the most common autoimmune disease, affecting 3-5% patients worldwide. In recent years, approximately 200 articles on AIT have been published annually in various journals. However, to date, no article has systematically assessed the related literature. Therefore, we conducted a bibliometric analysis on AIT to reveal the dynamic scientific developments and help researchers gain a global perspective while exploring the hotspots and development trends. METHODS: AIT-related articles and reviews from 2000 to 2022 were retrieved from the Web of Science Core Collection (WoSCC). The following search terms were used to extract document data: TS= (" autoimmune thyroiditi*") OR TI= ("chronic lymphocytic thyroiditi*") OR TI=(hashimoto*) OR TI= ("postpartum thyroiditis"). We selected articles and reviews published in English from 2000 to 2022. Three software programs (VOSviewer, CiteSpace, Pajek) were employed to analyze the contribution and co-occurrence relationships of different references, countries/regions, institutes, journals and also keywords in this field. RESULTS: This scientometric study included 2290 English papers published in 723 journals with 39661 co-cited references from 561 institutions in 120 countries/regions. Based on the reference and keyword analysis, researchers used to focus on "apoptosis", "insulin resistance", "encephalopathy", "IFN-γ" related to AIT during the past 20 years. However, with the development of other novel directions such as "papillary thyroid cancer" (2018-2022), "Vitamin D" (2016-2022), "oxidative stress" (2018-2022), "polymorphism" (2019-2022) and "association" (2020-2022), researchers are more interested in the relationship between papillary thyroid carcinoma and AIT, the effect of vitamin D supplementation on AIT, the oxidative stress in thyroid disease as well as the influence of polymorphism. CONCLUSION: Bibliometric analysis of the outputs of AIT shows an overview of the current status of the research on AIT. The associations between papillary thyroid carcinoma, vitamin D, oxidative stress, polymorphism and AIT are major research frontiers. However, further research and collaboration are still required worldwide. Our findings can help researchers grasp the research status of AIT and quickly determine new directions for future research.
背景:自身免疫性甲状腺炎(AIT)是最常见的自身免疫性疾病,影响全球 3-5%的患者。近年来,每年在各种期刊上发表约 200 篇关于 AIT 的文章。然而,迄今为止,尚无文章对相关文献进行系统评估。因此,我们对 AIT 进行了文献计量分析,以揭示动态的科学发展,并帮助研究人员在探索热点和发展趋势时获得全球视角。
方法:从 Web of Science 核心合集(WoSCC)中检索了 2000 年至 2022 年与 AIT 相关的文章和综述。使用以下搜索词提取文献数据:TS=("自身免疫性甲状腺炎")或 TI=("慢性淋巴细胞性甲状腺炎")或 TI=(hashimoto*)或 TI=("产后甲状腺炎")。我们选择了 2000 年至 2022 年期间以英语发表的文章和综述。使用三个软件程序(VOSviewer、CiteSpace、Pajek)分析该领域不同参考文献、国家/地区、机构、期刊和关键词的贡献和共现关系。
结果:这项科学计量研究包括来自 120 个国家/地区的 561 个机构的 723 种期刊上发表的 2290 篇英文论文,以及 39661 篇共同引用文献。基于参考文献和关键词分析,研究人员在过去 20 年中主要关注与 AIT 相关的"细胞凋亡"、"胰岛素抵抗"、"脑病"、"IFN-γ"。然而,随着其他新方向的发展,如"甲状腺乳头状癌"(2018-2022 年)、"维生素 D"(2016-2022 年)、"氧化应激"(2018-2022 年)、"多态性"(2019-2022 年)和"关联"(2020-2022 年),研究人员对甲状腺乳头状癌与 AIT 的关系、维生素 D 补充对 AIT 的影响、甲状腺疾病中的氧化应激以及多态性的影响更感兴趣。
结论:对 AIT 研究成果的文献计量分析展示了 AIT 研究现状的概述。甲状腺乳头状癌、维生素 D、氧化应激、多态性与 AIT 之间的关联是主要的研究前沿。然而,全球仍需要进一步的研究和合作。我们的研究结果可以帮助研究人员掌握 AIT 的研究现状,并快速确定未来研究的新方向。
Front Endocrinol (Lausanne). 2023
Front Endocrinol (Lausanne). 2023
Front Endocrinol (Lausanne). 2023
Front Endocrinol (Lausanne). 2023
Oxid Med Cell Longev. 2023
Front Med (Lausanne). 2024-5-20
J Med Biochem. 2025-7-4
Front Psychiatry. 2025-7-23
Endocr Connect. 2025-8-11
Med Sci (Basel). 2025-4-10
Int J Mol Sci. 2024-10-25
Front Endocrinol (Lausanne). 2024
J Cancer Epidemiol. 2024-8-26
Front Endocrinol (Lausanne). 2024
Front Endocrinol (Lausanne). 2022
Front Med (Lausanne). 2022-2-17
Front Public Health. 2022
J Endocrinol Invest. 2022-7